Overview

Gout Dose Response Study

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
Phase:
Phase 2
Details
Lead Sponsor:
Ardea Biosciences, Inc.
Treatments:
Lesinurad